Diffuse melanosis cutis: a rare manifestation of metastatic melanoma. Issue 8 (30th August 2019)

• Record Type: Journal Article
• Authors: Chinai, Brian; Piazza, Michael; Patel, Ritesh; Roy, Satyajeet
• Is Part Of: BMJ case reports. Volume 12:Issue 8(2019)
• Publication Date: 2019-08-30
• Subjects: cancer intervention -- dermatology -- skin cancer; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2019-230396
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : Diffuse melanosis cutis (DMC) is an extremely rare and late complication of metastatic melanoma (MM). It involves the progressive blue-grey discolouration of the skin and mucous membranes, occurring approximately 1 year after diagnosis of MM. The pathogenesis of DMC is unknown, although specific growth factors, such as alpha-melanocyte stimulating hormone, hepatocyte growth factor and endothelin-1, released by cancer cells, along with release of melanin precursors in the bloodstream and dermal MM micrometastases producing melanin have been attributed. Even with appropriate therapy, DMC seems to be a poor prognostic factor, with a mean survival time of 4–5 months. Here, we report a case of BRAF-mutated MM who presented with DMC. The patient underwent BRAF/MEK inhibition followed by anti-PDL1 therapy, yet passed away approximately 1 year after diagnosis.